Business
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced the enrollment of the first patient in the landmark BENEFIT-HF trial at North Central Heart - a division of the Avera Heart Hospital, in Sioux Falls, S.D. by Dr. Orvar Jonsson. BENEFIT-HF is expected to be one of the largest therapeutic cardiac devi
About this update from Cvrx, Inc.
[{"type":"image","alt":"CVRx, Inc.","displaySize":"","headline":null,"caption":"CVRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/df09df0c7616e5d7c04e1cae1c854256"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jMCkCGQ7b_B17NxKmbJDHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Nw--/https://media.zenfs.com/en/globenewswire.com/df09df0c7616e5d7c04e1cae1c854256","width":300,"height":119}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced the enrollment of the first patient in the landmark BENEFIT-HF trial at North Central Heart - a division of the Avera Heart Hospital, in Sioux Falls, S.D. by Dr. Orvar Jonsson.","length":427,"tagName":"p"},{"type":"text","content":"BENEFIT-HF is expected to be one of the largest therapeutic cardiac device trials ever performed in heart failure, enrolling 2,500 patients at approximately 150 centers in the United States and Germany. The prospective, randomized, controlled, multicenter trial is supported by CMS Category B IDE coverage and designed to evaluate all-cause mortality and heart failure decompensation events in a significantly expanded heart failure population.","length":444,"tagName":"p"},{"type":"text","content":"“We are honored to enroll the first patient in the BENEFIT-HF trial,” said Dr. Orvar Jonsson, North Central Heart - a division of the Avera Heart Hospital. “This study will evaluate Barostim therapy in a broader population of patients who remain symptomatic despite optimized guideline-directed medical therapy, generating important data that will further define Barostim’s position in the heart failure continuum.”","length":415,"tagName":"p"},{"type":"text","content":"“Achievement of this early milestone reflects tremendous excitement in the healthcare community regarding this landmark trial, and strong execution by the CVRx team in partnership with BENEFIT-HF investigators,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “We are proud to collaborate with leading physicians in development of such meaningful clinical evidence, and excited to further charac...